Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s

 
• By Alaric DeArment
  
Geron announced Phase III results for imetelstat in lower-risk myelodysplastic syndrome • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas